Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: Implications for drug design

被引:104
作者
Engh, RA
Brandstetter, H
Sucher, G
Eichinger, A
Baumann, U
Bode, W
Huber, R
Poll, T
Rudolph, R
vonderSaal, W
机构
[1] BOEHRINGER MANNHEIM GMBH, D-68305 MANNHEIM, GERMANY
[2] BOEHRINGER MANNHEIM GMBH, D-82372 PENZBERG, GERMANY
关键词
anticoagulant; drug design; protein flexibility; thrombin; weak interactions; X-ray crystallography;
D O I
10.1016/S0969-2126(96)00142-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The explosive growth in the rate of X-ray determination of protein structures is fuelled largely by the expectation that structural information will be useful for pharmacological and biotechnological applications. For example, there have been intensive efforts to develop orally administrable antithrombotic drugs using information about the crystal structures of blood coagulation factors, including thrombin. Most of the low molecular weight thrombin inhibitors studied so far are based on arginine and benzamidine. We sought to expand the database of information on thrombin-inhibitor binding by studying new classes of inhibitors. Results: We report the structures of three new inhibitors complexed with thrombin, two based on 4-aminopyridine and one based on naphthamidine. We observe several geometry changes in the protein main chain and side chains which accompany inhibitor binding. The two inhibitors based on 4-aminopyridine bind in notably different ways: one forms a water-mediated hydrogen bond to the active site Ser195, the other induces a rotation of the Ser214-Trp215 peptide plane that is unprecedented in thrombin structures. These binding modes also differ in their 'weak' interactions, including CH-O hydrogen bonds and interactions between water molecules and aromatic pi-clouds. Induced-fit structural changes were also seen in the structure of the naphthamidine inhibitor complex. Conclusions: Protein flexibility and variable water structures are essential elements in protein-ligand interactions. Ligand design strategies that fail to take this into account may overlook or underestimate the potential of lead structures. Further, the significance of 'weak' interactions must be considered both in crystallographic refinement and in analysis of binding mechanisms. (C) Current Biology Ltd
引用
收藏
页码:1353 / 1362
页数:10
相关论文
共 51 条
  • [1] BANNER DW, 1991, J BIOL CHEM, V266, P20085
  • [2] THE X-RAY CRYSTAL-STRUCTURE OF THROMBIN IN COMPLEX WITH N-ALPHA-2-NAPHTHYLSULFONYL-L-3-AMIDINO-PHENYLALANYL-4-METHYLPIPERIDIDE - THE BENEFICIAL EFFECT OF FILLING OUT AN EMPTY CAVITY
    BERGNER, A
    BAUER, M
    BRANDSTETTER, H
    STURZEBECHER, J
    BODE, W
    [J]. JOURNAL OF ENZYME INHIBITION, 1995, 9 (01): : 101 - +
  • [3] PROTEIN DATA BANK - COMPUTER-BASED ARCHIVAL FILE FOR MACROMOLECULAR STRUCTURES
    BERNSTEIN, FC
    KOETZLE, TF
    WILLIAMS, GJB
    MEYER, EF
    BRICE, MD
    RODGERS, JR
    KENNARD, O
    SHIMANOUCHI, T
    TASUMI, M
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1977, 112 (03) : 535 - 542
  • [4] THE REFINED 1.9 A CRYSTAL-STRUCTURE OF HUMAN ALPHA-THROMBIN - INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT
    BODE, W
    MAYR, I
    BAUMANN, U
    HUBER, R
    STONE, SR
    HOFSTEENGE, J
    [J]. EMBO JOURNAL, 1989, 8 (11) : 3467 - 3475
  • [5] BODE W, 1992, PROTEIN SCI, V1, P426
  • [6] X-RAY STRUCTURE OF CLOTTING FACTOR IXA - ACTIVE-SITE AND MODULE STRUCTURE RELATED TO XASE ACTIVITY AND HEMOPHILIA-B
    BRANDSTETTER, H
    BAUER, M
    HUBER, R
    LOLLAR, P
    BODE, W
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (21) : 9796 - 9800
  • [7] REFINED 2.3-ANGSTROM X-RAY CRYSTAL-STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA - A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
    BRANDSTETTER, H
    TURK, D
    HOEFFKEN, HW
    GROSSE, D
    STURZEBECHER, J
    MARTIN, PD
    EDWARDS, BFP
    BODE, W
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1992, 226 (04) : 1085 - 1099
  • [8] BRANDSTETTER H, 1996, IN PRESS J BIOL CHEM, V271
  • [9] BRUNGER AT, 1993, XPLOR VERSION 3 1 SY
  • [10] DRUGS BY DESIGN
    BUGG, CE
    CARSON, WM
    MONTGOMERY, JA
    [J]. SCIENTIFIC AMERICAN, 1993, 269 (06) : 92 - 98